The Board of Directors approved an option repricing for approximately 4.05 million underwater stock options held by continuing employees, lowering the exercise price from a range of $6.48 to $33.11 down to $1.87 per share. The new rate matches the closing stock price on October 13, 2026. To ensure retention, employees exercising these repriced options before the end of a one-year Retention Period must pay a premium equal to their original exercise price. This action aims to motivate key personnel without incurring additional dilution from new grants or cash expenditures. Alector is a biotechnology company focused on developing therapies for neurodegenerative diseases.
